Multiple myeloma (MM) is characterized by the proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraproteins (M proteins). Everolimus works similarly to sirolimus as a mammalian target of rapamycin (mTOR) inhibitor. Bortezomib was the first therapeutic proteasome inhibitor to be tested in humans with MM. However, the combination of these two drugs for the treatment of MM has been rarely reported. In this study, we compared the therapeutic effects of everolimus and bortezomib, as well as those of a combination of everolimus and bortezomib, using an in vitro MM cell line model and in vivo xenograft mouse model. Our results showed that the synergistic antitumor effects of everolimus and bortezomib have significant inhibitory effect through inhibition of the AKT/mTOR pathway in both the MM cell lines and MM-bearing mice model. Our results provided evidence that the mTOR inhibitor, everolimus, will be a potential drug in MM therapy.
Get full access to this article
View all access options for this article.
References
1.
ChouT. Multiple myeloma: recent progress in diagnosis and treatment. J Clin Exp Hematop2012;52:149–59.doi:10.3960/jslrt.52.149
2.
SiegelR, MaJ, ZouZ, . Cancer statistics, 2014. CA Cancer J Clin2014;64:9–29.doi:10.3322/caac.21208
3.
WangQ, WangY, JiZ, . Risk factors for multiple myeloma: a hospital-based case-control study in Northwest China. Cancer Epidemiol2012;36:439–44.doi:10.1016/j.canep.2012.05.002
4.
Chan ChungKC, TiedemannRE. Getting to the root of the problem: the causes of relapse in multiple myeloma. Expert Rev Anticancer Ther2014;14:251–4.doi:10.1586/14737140.2014.868776
5.
AdamsJ. The proteasome: a suitable antineoplastic target. Nat Rev Cancer2004;4:349–60.doi:10.1038/nrc1361
6.
QinJZ, ZiffraJ, StennettL, . Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res2005;65:6282–93.doi:10.1158/0008-5472.CAN-05-0676
7.
OshikawaG, KojimaA, DokiN, . Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med2013;52:111–4.doi:10.2169/internalmedicine.52.8799
8.
AléA, BrunaJ, HerrandoM, . Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice. Neurotox Res2015;27:430–40.doi:10.1007/s12640-014-9514-8
9.
MuraiK, KowataS, ShimoyamaT, . Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. Eur J Haematol2014;93:290–6.doi:10.1111/ejh.12342
10.
ZaytsevaYY, ValentinoJD, GulhatiP, . mTOR inhibitors in cancer therapy. Cancer Lett2012;319:1–7.doi:10.1016/j.canlet.2012.01.005
11.
VitkoS, TedescoH, ErisJ, . Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant2004;4:626–35.doi:10.1111/j.1600-6143.2004.00389.x
12.
MotzerRJ, EscudierB, OudardS, . Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer2010;116:4256–65.doi:10.1002/cncr.25219
13.
YaoJC, ShahMH, ItoT, . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med2011;364:514–23.doi:10.1056/NEJMoa1009290
14.
FranzDN, BelousovaE, SparaganaS, . Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet2013;381:125–32.doi:10.1016/S0140-6736(12)61134-9
15.
LaubachJP, MoslehiJJ, FrancisSA, . A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol2017;178:547–60.doi:10.1111/bjh.14708
16.
ChristopoulosP, Engel-RiedelW, GrohéC, . Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol2017;28:1898–902.doi:10.1093/annonc/mdx268
17.
WangM, PopplewellLL, CollinsRH, . Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol2014;165:510–8.doi:10.1111/bjh.12780
18.
UtechtKN, KolesarJ. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm2008;65:1221–31.doi:10.2146/ajhp070272
19.
GhobrialIM, ReddR, ArmandP, . Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia2015;29:2338–46.doi:10.1038/leu.2015.164
20.
LiuX, FengQ, BachhukaA, . Surface modification by allylamine plasma polymerization promotes osteogenic differentiation of human adipose-derived stem cells. ACS Appl Mater Interfaces2014;6:9733–41.doi:10.1021/am502170s
21.
ScutoA, KirschbaumM, KowolikC, . The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood2008;111:5093–100.doi:10.1182/blood-2007-10-117762
22.
AsanoJ, NakanoA, OdaA, . The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia2011;25:1182–8.doi:10.1038/leu.2011.60
23.
MaZ, ChenX, HuangY, . MR diffusion-weighted imaging-based subcutaneous tumour volumetry in a xenografted nude mouse model using 3D Slicer: an accurate and repeatable method. Sci Rep2015;5:15653.doi:10.1038/srep15653
24.
ChouTC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev2006;58:621–81.doi:10.1124/pr.58.3.10
KeatingMJ, BachC, YasothanU, . Bendamustine. Nat Rev Drug Discov2008;7:473–4.doi:10.1038/nrd2596
27.
LiX, AlafuzoffI, SoininenH, . Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. Febs J2005;272:4211–20.doi:10.1111/j.1742-4658.2005.04833.x
28.
TamKH, YangZF, LauCK, . Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett2009;273:201–9.doi:10.1016/j.canlet.2008.08.018
29.
ShiY, YanH, FrostP, . Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther2005;4:1533–40.doi:10.1158/1535-7163.MCT-05-0068
30.
BuckE, EyzaguirreA, BrownE, . Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther2006;5:2676–84.doi:10.1158/1535-7163.MCT-06-0166
